Role of Plasma EBV DNA Levels in Predicting Recurrence of Nasopharyngeal Carcinoma in a Western Population

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2012 Jun 1

PMID 22646734

Citations 28

Authors

Daris Ferrari

Carla Codeca

Cecilia Bertuzzi

Francesca Broggio

Francesca Crepaldi

Andrea Luciani

Irene Floriani

Mohssen Ansarin

Fausto Chiesa

Daniela Alterio

Paolo Foa

Affiliations

Soon will be listed here.

Abstract

Background: Loco-regionally advanced nasopharyngeal carcinomas can be cured by the combination of chemotherapy and radiotherapy. In Eastern countries, plasma levels of viral Epstein-Barr deoxyribonucleic acid (DNA) are accurate in predicting recurrence, but few data are available in Western populations. The aim of this prospective study was to evaluate the relationship between viral Epstein-Barr DNA copy numbers in plasma and the response rate, progression-free survival and overall survival in a cohort of Western patients with stage IIb-IVb nasopharyngeal cancer.

Methods: We evaluated plasma samples from 36 consecutive patients treated with induction chemotherapy followed by chemoradiation. EBV copy numbers were determined after DNA extraction using real-time quantitative polymerase chain reaction. Survival curves were estimated using the Kaplan-Meier method.

Results: Circulating Epstein-Barr virus DNA levels were measured before treatment, at the end of concomitant chemo- and radiotherapy, and during the follow-up period. Pre-treatment levels significantly correlated with the initial stage and probability of relapse. Their increase was 100% specific and 71.3% sensitive in detecting loco-regional or metastatic recurrence (an overall accuracy of 94.4%). Three-year progression-free and overall survival were respectively 78.2% and 97.1%.

Conclusions: The results of this study confirm that patients from a Western country affected by loco-regionally advanced nasopharyngeal carcinoma have high plasma Epstein-Barr virus DNA levels at diagnosis. The monitoring of plasma levels is sensitive and highly specific in detecting disease recurrence and metastases.

Citing Articles

Metabolic reprogramming in the pathogenesis and progression of nasopharyngeal carcinoma: molecular mechanisms and therapeutic implications.

Wang H, Hu J, Zhou W, Qian A Am J Cancer Res. 2024; 14(8):4049-4064.

PMID: 39267663 PMC: 11387871. DOI: 10.62347/VYAT9271.

Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial.

Lee N, Harris J, Kim J, Garden A, Mechalakos J, Pfister D JAMA Netw Open. 2023; 6(6):e2316094.

PMID: 37266942 PMC: 10238946. DOI: 10.1001/jamanetworkopen.2023.16094.

Association Between Mortality Due to Nasopharyngeal Carcinoma and Race in the United States From 2007 to 2016.

Raslan S, Rodriguez E, Zheng C, Lozano J, Barengo N, Sargi Z Asian Pac J Cancer Prev. 2023; 24(3):915-921.

PMID: 36974545 PMC: 10334084. DOI: 10.31557/APJCP.2023.24.3.915.

Impact of primary site on survival in patients with nasopharyngeal carcinoma from 2004 to 2015.

Shen T, Cai W, Li T, Yu D, Ren C, Yu J Front Surg. 2022; 9:1001849.

PMID: 36406355 PMC: 9671952. DOI: 10.3389/fsurg.2022.1001849.

The Promise of Circulating Tumor DNA in Head and Neck Cancer.

Aulakh S, Silverman D, Young K, Dennis S, Birkeland A Cancers (Basel). 2022; 14(12).

PMID: 35740633 PMC: 9221491. DOI: 10.3390/cancers14122968.

References

Gulley M . Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn. 2001; 3(1):1-10. PMC: 1907346. DOI: 10.1016/S1525-1578(10)60642-3. View

Leong S, Wee J, Tay M, Toh C, Tan S, Thng C . Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. Cancer. 2004; 103(3):569-75. DOI: 10.1002/cncr.20804. View

Lo Y, Chan L, Chan A, Leung S, Lo K, Zhang J . Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999; 59(21):5452-5. View

Wang W, Twu C, Lin W, Jiang R, Liang K, Chen K . Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma. Cancer. 2011; 117(19):4452-9. DOI: 10.1002/cncr.26069. View

Chan A, Lo Y, Zee B, Chan L, Ma B, Leung S . Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002; 94(21):1614-9. DOI: 10.1093/jnci/94.21.1614. View

Bortolin M, Pratesi C, Dolcetti R, Bidoli E, Vaccher E, Zanussi S . Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Lett. 2005; 233(2):247-54. DOI: 10.1016/j.canlet.2005.03.015. View

Chou J, Lin Y, Kim J, You L, Xu Z, He B . Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck. 2008; 30(7):946-63. PMC: 3046044. DOI: 10.1002/hed.20833. View

Lo Y, Chan L, Lo K, Leung S, Zhang J, Chan A . Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999; 59(6):1188-91. View

Parkin D, Bray F, Devesa S . Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37 Suppl 8:S4-66. DOI: 10.1016/s0959-8049(01)00267-2. View

10.

Marks J, Phillips J, Menck H . The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer. 1998; 83(3):582-8. DOI: 10.1002/(sici)1097-0142(19980801)83:3<582::aid-cncr29>3.0.co;2-r. View

11.

Li Y, Wang F, Jiang W, Xiang X, Deng Y, Hu G . Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2008; 62(3):539-44. DOI: 10.1007/s00280-007-0641-2. View

12.

Ji M, Yu Y, Cheng W, Zong Y, Ng P, Chua D . Detection of Stage I nasopharyngeal carcinoma by serologic screening and clinical examination. Chin J Cancer. 2011; 30(2):120-3. PMC: 4013341. DOI: 10.5732/cjc.010.10595. View

13.

Fahraeus R, Fu H, Ernberg I, Finke J, Rowe M, Klein G . Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer. 1988; 42(3):329-38. DOI: 10.1002/ijc.2910420305. View

14.

Wang W, Twu C, Chen H, Jan J, Jiang R, Chao J . Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res. 2010; 16(3):1016-24. DOI: 10.1158/1078-0432.CCR-09-2796. View

15.

Devi B, Pisani P, Tang T, Parkin D . High incidence of nasopharyngeal carcinoma in native people of Sarawak, Borneo Island. Cancer Epidemiol Biomarkers Prev. 2004; 13(3):482-6. View

16.

Zeng Y, Zhang L, Wu Y, Huang Y, Huang N, Li J . Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer. 1985; 36(5):545-7. DOI: 10.1002/ijc.2910360505. View

17.

Mainou B, Raab-Traub N . LMP1 strain variants: biological and molecular properties. J Virol. 2006; 80(13):6458-68. PMC: 1488979. DOI: 10.1128/JVI.00135-06. View

18.

Hou X, Zhao C, Guo Y, Han F, Lu L, Wu S . Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy. Clin Oncol (R Coll Radiol). 2010; 23(2):128-33. DOI: 10.1016/j.clon.2010.09.001. View

19.

Lin J, Wang W, Chen K, Wei Y, Liang W, Jan J . Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350(24):2461-70. DOI: 10.1056/NEJMoa032260. View

20.

Nielsen N, Mikkelsen F, Hansen J . Nasopharyngeal cancer in Greenland. The incidence in an Arctic Eskimo population. Acta Pathol Microbiol Scand A. 1977; 85(6):850-8. View